182 related articles for article (PubMed ID: 10821776)
1. Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonist, JTT-501, on diabetic complications in Zucker diabetic fatty rats.
Shibata T; Takeuchi S; Yokota S; Kakimoto K; Yonemori F; Wakitani K
Br J Pharmacol; 2000 Jun; 130(3):495-504. PubMed ID: 10821776
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative.
Shibata T; Matsui K; Nagao K; Shinkai H; Yonemori F; Wakitani K
Eur J Pharmacol; 1999 Jan; 364(2-3):211-9. PubMed ID: 9932726
[TBL] [Abstract][Full Text] [Related]
3. A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat.
Brown KK; Henke BR; Blanchard SG; Cobb JE; Mook R; Kaldor I; Kliewer SA; Lehmann JM; Lenhard JM; Harrington WW; Novak PJ; Faison W; Binz JG; Hashim MA; Oliver WO; Brown HR; Parks DJ; Plunket KD; Tong WQ; Menius JA; Adkison K; Noble SA; Willson TM
Diabetes; 1999 Jul; 48(7):1415-24. PubMed ID: 10389847
[TBL] [Abstract][Full Text] [Related]
4. Effects of type-2 diabetes and troglitazone on the expression patterns of small intestinal sugar transporters and PPAR-gamma in the Zucker diabetic fatty rat.
Corpe C; Sreenan S; Burant C
Digestion; 2001; 63(2):116-23. PubMed ID: 11244250
[TBL] [Abstract][Full Text] [Related]
5. [The chemical structure and pharmacological properties of a novel isoxazolidinedione insulin sensitizer, JTT-501].
Shinkai H
Nihon Rinsho; 2001 Nov; 59(11):2207-10. PubMed ID: 11712409
[TBL] [Abstract][Full Text] [Related]
6. Tissue-specific actions of antidiabetic thiazolidinediones on the reduced fatty acid oxidation in skeletal muscle and liver of Zucker diabetic fatty rats.
Ide T; Nakazawa T; Mochizuki T; Murakami K
Metabolism; 2000 Apr; 49(4):521-5. PubMed ID: 10778879
[TBL] [Abstract][Full Text] [Related]
7. Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats.
Ma LJ; Marcantoni C; Linton MF; Fazio S; Fogo AB
Kidney Int; 2001 May; 59(5):1899-910. PubMed ID: 11318962
[TBL] [Abstract][Full Text] [Related]
8. A novel peroxisome proliferator-activated receptor (PPAR)gamma agonist, NIP-222, reduces urinary albumin excretion in streptozotocin-diabetic mice independent of PPARgamma activation.
Yotsumoto T; Naitoh T; Kanaki T; Matsuda M; Tsuruzoe N
Metabolism; 2003 Dec; 52(12):1633-7. PubMed ID: 14669169
[TBL] [Abstract][Full Text] [Related]
9. A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models.
Etgen GJ; Oldham BA; Johnson WT; Broderick CL; Montrose CR; Brozinick JT; Misener EA; Bean JS; Bensch WR; Brooks DA; Shuker AJ; Rito CJ; McCarthy JR; Ardecky RJ; Tyhonas JS; Dana SL; Bilakovics JM; Paterniti JR; Ogilvie KM; Liu S; Kauffman RF
Diabetes; 2002 Apr; 51(4):1083-7. PubMed ID: 11916929
[TBL] [Abstract][Full Text] [Related]
10. Up-regulation of peroxisome proliferator-activated receptors (PPAR-alpha) and PPAR-gamma messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-gamma-responsive adipose tissue-specific genes in the liver of obese diabetic mice.
Memon RA; Tecott LH; Nonogaki K; Beigneux A; Moser AH; Grunfeld C; Feingold KR
Endocrinology; 2000 Nov; 141(11):4021-31. PubMed ID: 11089532
[TBL] [Abstract][Full Text] [Related]
11. Rosiglitazone prevents the onset of hyperglycaemia and proteinuria in the Zucker diabetic fatty rat.
Smith SA; Lister CA; Toseland CD; Buckingham RE
Diabetes Obes Metab; 2000 Dec; 2(6):363-72. PubMed ID: 11225966
[TBL] [Abstract][Full Text] [Related]
12. Troglitazone halts diabetic glomerulosclerosis by blockade of mesangial expansion.
McCarthy KJ; Routh RE; Shaw W; Walsh K; Welbourne TC; Johnson JH
Kidney Int; 2000 Dec; 58(6):2341-50. PubMed ID: 11115068
[TBL] [Abstract][Full Text] [Related]
13. Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes.
Shimabukuro M; Zhou YT; Levi M; Unger RH
Proc Natl Acad Sci U S A; 1998 Mar; 95(5):2498-502. PubMed ID: 9482914
[TBL] [Abstract][Full Text] [Related]
14. Role of PPAR-gamma ligands in neuroprotection against glutamate-induced cytotoxicity in retinal ganglion cells.
Aoun P; Simpkins JW; Agarwal N
Invest Ophthalmol Vis Sci; 2003 Jul; 44(7):2999-3004. PubMed ID: 12824244
[TBL] [Abstract][Full Text] [Related]
15. Peroxisome proliferator-activated receptor (PPAR) gamma and retinoid X receptor (RXR) agonists have complementary effects on glucose and lipid metabolism in human skeletal muscle.
Cha BS; Ciaraldi TP; Carter L; Nikoulina SE; Mudaliar S; Mukherjee R; Paterniti JR; Henry RR
Diabetologia; 2001 Apr; 44(4):444-52. PubMed ID: 11357475
[TBL] [Abstract][Full Text] [Related]
16. Unique ability of troglitazone to up-regulate peroxisome proliferator-activated receptor-gamma expression in hepatocytes.
Davies GF; McFie PJ; Khandelwal RL; Roesler WJ
J Pharmacol Exp Ther; 2002 Jan; 300(1):72-7. PubMed ID: 11752099
[TBL] [Abstract][Full Text] [Related]
17. Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone.
Camp HS; Li O; Wise SC; Hong YH; Frankowski CL; Shen X; Vanbogelen R; Leff T
Diabetes; 2000 Apr; 49(4):539-47. PubMed ID: 10871190
[TBL] [Abstract][Full Text] [Related]
18. Direct thiazolidinedione action on isolated rat skeletal muscle fuel handling is independent of peroxisome proliferator-activated receptor-gamma-mediated changes in gene expression.
Brunmair B; Gras F; Neschen S; Roden M; Wagner L; Waldhäusl W; Fürnsinn C
Diabetes; 2001 Oct; 50(10):2309-15. PubMed ID: 11574413
[TBL] [Abstract][Full Text] [Related]
19. Effects of the dual PPAR-α/γ agonist aleglitazar on glycaemic control and organ protection in the Zucker diabetic fatty rat.
Bénardeau A; Verry P; Atzpodien EA; Funk JM; Meyer M; Mizrahi J; Winter M; Wright MB; Uhles S; Sebokova E
Diabetes Obes Metab; 2013 Feb; 15(2):164-74. PubMed ID: 22958363
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy of an intestine-specific inhibitor of microsomal triglyceride transfer protein and peroxisome proliferator-activated receptor γ agonist in diabetic rat.
Sakata S; Mera Y; Kuroki Y; Nashida R; Kakutani M; Ohta T
J Diabetes Res; 2014; 2014():890639. PubMed ID: 24772450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
